MariTide (maridebart cafraglutide): Mechanism, Trials, and What the Data Actually Shows
MariTide (maridebart cafraglutide) is a Phase 3 program from Amgen built around GLP-1 agonist + GIP antagonist. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Amgen
Mechanism
GLP-1 agonist + GIP antagonist
Stage
Phase 3
Tracked in
Dual agonists
Approval and timeline
Need the straight approval read on MariTide (maridebart cafraglutide)?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View MariTide (maridebart cafraglutide) statusCompound facts for search and AI answers
What this MariTide (maridebart cafraglutide) tracking page answers
Compound
MariTide (maridebart cafraglutide) from Amgen
MariTide (maridebart cafraglutide) is tracked in the dual agonists group.
Mechanism
GLP-1 agonist + GIP antagonist
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 3
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Evidence read
No mature public weight-loss signal pinned yet
MariTide (maridebart cafraglutide) should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Clinical evidence snapshot
What the evidence can and cannot say about MariTide (maridebart cafraglutide)
MariTide (maridebart cafraglutide) should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is MariTide (maridebart cafraglutide) available now or watchlist only?
MariTide (maridebart cafraglutide) should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- MariTide (maridebart cafraglutide)
- Developer
- Amgen
- Stage
- Phase 3
- Mechanism
- Dual agonists
Step 1
Read the stage first
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is MariTide (maridebart cafraglutide)?
MariTide (maridebart cafraglutide) is a phase 3 obesity or metabolic program from Amgen built around GLP-1 agonist + GIP antagonist.
Is MariTide (maridebart cafraglutide) approved?
No. MariTide is still in Phase 3. It has real late-stage importance, but it is not yet an FDA-approved broad obesity product.
When could it matter?
2027 to 2028 if Amgen converts the mechanism into a clean filing story.
What MariTide (maridebart cafraglutide) is
MariTide (maridebart cafraglutide) is part of the dual agonists cluster in the FormBlends obesity-pipeline map. We track it because Amgen is using GLP-1 agonist + GIP antagonist as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program is in late-stage development, which means FormBlends treats it as a real near-term market-moving asset. At this point, the focus shifts from basic proof of concept to readout quality, safety signals, filing strategy, and manufacturing readiness.
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.
What FormBlends is watching next
For MariTide (maridebart cafraglutide), the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
More dual agonists on FormBlends
Frequently asked questions
What is MariTide (maridebart cafraglutide)?
MariTide (maridebart cafraglutide) is a Phase 3 obesity or metabolic compound from Amgen. FormBlends tracks it in the dual agonists group and follows it for trial progress, regulatory movement, and competitive impact.
How does MariTide (maridebart cafraglutide) work?
MariTide (maridebart cafraglutide) is being tracked as a GLP-1 agonist + GIP antagonist program. That mechanism is the main reason it sits inside the dual agonists bucket of the 2026 obesity pipeline.
Is MariTide (maridebart cafraglutide) available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking MariTide (maridebart cafraglutide)?
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.